Skip to main content
TITAN PHARMACEUTICALS INC logo

TITAN PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · TTNP ISIN · US8883146065 LEI · 549300NOUZGB2ZNVJ794 US Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2011-02-11 Major Shareholding Noti…
Country US United States of America
Listing US TTNP

About TITAN PHARMACEUTICALS INC

https://www.titanpharm.com/

Titan Pharmaceuticals, Inc. is a development-stage biopharmaceutical company that develops proprietary therapeutics using its clinically proven ProNeura® technology, a long-term, continuous drug delivery platform. This platform is designed for the administration of medicines to treat select chronic diseases. The ProNeura system involves a small, solid implant that is placed subdermally and provides continuous, non-fluctuating blood levels of a drug for an extended period. The company's development efforts have historically focused on treatments for central nervous system disorders.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2011
Major Shareholding Notification
2011-02-11 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, a current report filed with the SEC to announce specific events. It includes a press release about the expected receipt of a royalty payment, attached as an exhibit. The document is short (2321 characters) and primarily serves as an announcement rather than a detailed financial report. It does not contain comprehensive financial statements or detailed analysis. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-02-04 English
FORM 8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated December 27, 2010. It reports amendments to employment agreements of two officers, including compensation details and extensions. The key section is Item 5.02, which relates to the departure, election, or appointment of directors or officers and their compensatory arrangements. This matches the description of Board/Management Information filings, which announce changes or updates in senior management or board members. The document is not a full annual or quarterly report, nor is it an earnings release or proxy statement. It is not a regulatory filing of miscellaneous nature but specifically relates to management changes and compensation amendments. Therefore, the appropriate classification is MANG (Board/Management Information). The document length is 3561 characters, which is consistent with a detailed announcement rather than a brief notice or a full report. Confidence is high due to clear identification of management employment agreement amendments.
2010-12-29 English
REGISTRATION STATEMENT ON FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Registration Statement on Form S-8 filed with the SEC. Form S-8 is used for registering securities to be offered under employee benefit plans, such as stock option plans. The text includes details about stock option plans, indemnification of directors and officers, and references to other SEC filings incorporated by reference. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits the category of Regulatory Filings (RNS). The document length and content confirm it is the registration statement itself, not an announcement of a report.
2010-12-15 English
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2010
Interim / Quarterly Report Q3 2010
2010-11-15 English
FORM 4/A
Director's Dealing
2010-11-01 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.